Shree Ganesh Remedies Ltd Valuation Shifts Signal Elevated Price Risk

Valuation Metrics and Recent Changes

As of 6 April 2026, Shree Ganesh Remedies Ltd trades at ₹475.00, up 5.73% from the previous close of ₹449.25. The stock's 52-week range spans from ₹381.10 to ₹828.00, indicating significant volatility over the past year. The company’s current P/E ratio stands at 33.71, a level that has pushed its valuation grade from fair to expensive. This is a substantial premium compared to some of its peers, such as Bliss GVS Pharma, which holds a fair valuation with a P/E of 22.41, and Venus Remedies, trading at a P/E of 15.91.

Similarly, the price-to-book value ratio for Shree Ganesh Remedies has risen to 3.97, further signalling an expensive valuation relative to its book value. This contrasts with the sector average and some competitors who maintain lower P/BV ratios, reflecting more conservative market pricing.

Comparative Peer Analysis

When benchmarked against its peer group within the Pharmaceuticals & Biotechnology sector, Shree Ganesh Remedies’ valuation appears stretched. For instance, Kwality Pharma, also rated expensive, trades at a P/E of 25.86 and an EV/EBITDA of 14.75, both notably lower than Shree Ganesh Remedies’ EV/EBITDA of 18.30. More expensive peers like Shukra Pharma and NGL Fine Chem exhibit even higher P/E ratios of 47.89 and 37.78 respectively, but these companies often justify their premiums with stronger growth prospects or superior financial metrics.

On the other hand, companies such as Lincoln Pharma and Venus Remedies maintain fair valuations with P/E ratios of 14.02 and 15.91, respectively, suggesting that Shree Ganesh Remedies is trading at a premium that may not be fully supported by fundamentals.

Financial Performance and Returns Context

Shree Ganesh Remedies’ return profile over various periods presents a mixed picture. The stock has outperformed the Sensex over the short term, with a 1-week return of 1.84% compared to the Sensex’s decline of 2.60%. Over one month, the stock declined by 5.25%, but this was less severe than the Sensex’s 8.62% drop. Year-to-date, the stock has gained 2.55%, while the Sensex has fallen by 13.96%, indicating relative resilience.

However, the longer-term returns are less encouraging. Over the past year, Shree Ganesh Remedies has declined by 36.37%, significantly underperforming the Sensex’s 4.30% loss. Despite this, the company has delivered strong returns over three and five years, with gains of 90.34% and 82.15%, respectively, well above the Sensex’s 24.29% and 46.55% for the same periods. This suggests that while the stock has faced recent headwinds, its longer-term performance has been robust.

Profitability and Efficiency Metrics

From a profitability standpoint, Shree Ganesh Remedies reports a return on capital employed (ROCE) of 16.87% and a return on equity (ROE) of 11.79%. These figures indicate moderate efficiency in generating returns from capital and equity, though they are not exceptional within the sector. The company’s EV to EBIT ratio of 26.18 and EV to capital employed of 3.90 further reflect the market’s pricing of its earnings and capital base.

Notably, the PEG ratio is reported as zero, which may indicate either a lack of earnings growth or data unavailability, complicating growth-adjusted valuation assessments.

Market Capitalisation and Risk Profile

Shree Ganesh Remedies is classified as a micro-cap stock, which inherently carries higher volatility and risk compared to larger-cap peers. This is reflected in its Mojo Score of 26.0 and a recent downgrade from a Sell to a Strong Sell rating on 12 January 2026. The downgrade signals increased caution among analysts and investors, likely influenced by the stretched valuation and recent price volatility.

Price Attractiveness and Investment Implications

The shift in valuation from fair to expensive suggests that Shree Ganesh Remedies’ current price may not offer the same attractiveness it once did. Investors should weigh the premium valuation against the company’s moderate profitability and recent underperformance relative to the broader market. While the stock has demonstrated resilience in short-term returns and strong long-term gains, the elevated P/E and P/BV ratios imply that expectations for future growth are already priced in.

Given the micro-cap status and the Strong Sell rating, cautious investors might consider alternative stocks within the Pharmaceuticals & Biotechnology sector that offer more favourable valuation metrics and comparable or superior fundamentals. Companies such as Bliss GVS Pharma and Venus Remedies, with fair valuations and solid financials, could present more balanced risk-reward profiles.

Conclusion

In summary, Shree Ganesh Remedies Ltd’s valuation parameters have shifted notably, reflecting a more expensive market perception relative to its historical levels and peer group. While the company’s financial metrics and return history show strengths, the premium valuation and recent rating downgrade warrant careful consideration. Investors should closely monitor the company’s earnings trajectory and sector dynamics before committing fresh capital, especially given the availability of peers with more attractive valuations and potentially lower risk profiles.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today